// App-Quantinova.ai

1385 : Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Researchers

Presenter

  • Shambavi Richard

Principal Investigators

  • Sosana Delimpasi

  • Maryana Simonova

  • Ivan Spicka

  • Ludek Pour

  • Irina Kryachok

  • Meletios A Dimopoulos

  • Halyna Pylypenko

  • Holger W Auner

  • Xavier Leleu

  • Vadim A Doronin

  • Ganna Usenko

  • Roman Hajek

  • Reuben Benjamin

  • Tuphan Kanti Dolai

  • Dinesh Kumar Sinha

  • Christopher P. Venner

  • Mamta Garg

  • Don A. Stevens

  • Hang Quach

  • Sundar Jagannath

  • Philippe Moreau

  • Moshe Y. Levy

  • Ashraf Z. Badros

  • Larry D. Anderson Jr

  • Nizar Bahlis

  • Thierry Facon

  • Maria-Victoria Mateos

  • Michele Cavo

  • Hua Chang

  • Yosef Landesman

  • Anita A. Joshi

  • Yi Chai

  • Melina Arazy

  • Jatin Shah

  • Sharon Shacham

  • Michael G Kauffman

  • Sebastian Grosicki

  • Paul G. Richardson

Medical Centers

  • Icahn School of Medicine at Mt Sinai, Hematology/Oncology, Jersey City, NJ

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece

  • Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine, Lviv, Ukraine

  • Charles University General Hospital in Prague, Prague, Czech Republic.

  • University Hospital Brno, Brno, Czech Republic

  • Oncohematology, National Cancer Instititute, Kyiv, Ukraine

  • National and Kapodistrian University of Athens, Athens, Greece

  • Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine

  • Imperial College, London, United Kingdom

  • CHU Poitiers - Hopital La Miletrie, Poitiers, France

  • Moscow healthcare department, City Clinical Hospital No. 40, Moscow, Russian Federation

  • City Clinical Hospital No. 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine

  • University Hospital Brno and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Hematology, NRS Medical College, Kolkata, India

  • Indira Gandhi Institue of Medical Sciences, Patna, India

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Norton Cancer Institute - St Matthews Campus, Louisville, KY

  • Melbourne Blood Specialist, East Melbourne, VIC, Australia

  • Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Department of Hematology, CHU Nantes, Nantes, France

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD

  • UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX

  • University of Calgary, Calgary, AB, Canada

  • CHRU de Lille, Service des maladies du sang, Lille, France

  • Institute of Cancer Molecular and Cellular Biology,University Hospital of Salamanca,Salamanca,Spagna

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • Karyopharm Therapeutics, Newton, MA

  • Karyopharm Therapeutics, Newton, MA

  • Silesian Medical University, Katowice, Poland,

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Greece

  • Ukraine

  • Czech Republic

  • United Kingdom

  • France

  • Russia

  • India

  • Canada

  • Australia

  • Spain

  • Italy

  • Poland

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Syndecan-1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Selinexor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved